Schmaier A H, Bradford H, Silver L D, Farber A, Scott C F, Schutsky D, Colman R W
J Clin Invest. 1986 May;77(5):1565-73. doi: 10.1172/JCI112472.
Recent studies from our laboratory indicate that a high concentration of platelet-derived calcium-activated cysteine protease (calpain) can cleave high molecular weight kininogen (HMWK). On immunodiffusion and immunoblot, antiserum directed to the heavy chain of HMWK showed immunochemical identity with alpha-cysteine protease inhibitor--a major plasma inhibitor of tissue calpains. Studies were then initiated to determine whether purified or plasma HMWK was also an inhibitor of platelet calpain. Purified alpha-cysteine protease inhibitor, alpha-2-macroglobulin, as well as purified heavy chain of HMWK or HMWK itself inhibited purified platelet calpain. Kinetic analysis revealed that HMWK inhibited platelet calpain noncompetitively (Ki approximately equal to 5 nM). Incubation of platelet calpain with HMWK, alpha-2-macroglobulin, purified heavy chain of HMWK, or purified alpha-cysteine protease inhibitor under similar conditions resulted in an IC50 of 36, 500, 700, and 1,700 nM, respectively. The contribution of these proteins in plasma towards the inhibition of platelet calpain was investigated next. Normal plasma contained a protein that conferred a five to sixfold greater IC50 of purified platelet calpain than plasma deficient in either HMWK or total kininogen. Reconstitution of total kininogen deficient plasma with purified HMWK to normal levels (0.67 microM) completely corrected the subnormal inhibitory activity. However, reconstitution of HMWK deficient plasma to normal levels of low molecular weight kininogen (2.4 microM) did not fully correct the subnormal calpain inhibitory capacity of this plasma. These studies indicate that HMWK is a potent inhibitor as well as a substrate of platelet calpain and that the plasma and cellular kininogens may function as regulators of cytosolic, calcium-activated cysteine proteases.
我们实验室最近的研究表明,高浓度的血小板衍生的钙激活半胱氨酸蛋白酶(钙蛋白酶)可裂解高分子量激肽原(HMWK)。在免疫扩散和免疫印迹中,针对HMWK重链的抗血清显示与α-半胱氨酸蛋白酶抑制剂具有免疫化学同一性,α-半胱氨酸蛋白酶抑制剂是组织钙蛋白酶的主要血浆抑制剂。随后开展研究以确定纯化的或血浆中的HMWK是否也是血小板钙蛋白酶的抑制剂。纯化的α-半胱氨酸蛋白酶抑制剂、α-2-巨球蛋白,以及纯化的HMWK重链或HMWK本身均可抑制纯化的血小板钙蛋白酶。动力学分析显示,HMWK对血小板钙蛋白酶的抑制作用为非竞争性(Ki约等于5 nM)。在相似条件下,将血小板钙蛋白酶与HMWK、α-2-巨球蛋白、纯化的HMWK重链或纯化的α-半胱氨酸蛋白酶抑制剂一起孵育,其IC50分别为36、500、700和1700 nM。接下来研究了这些蛋白质在血浆中对血小板钙蛋白酶抑制作用的贡献。正常血浆中含有的一种蛋白质,使纯化的血小板钙蛋白酶的IC50比缺乏HMWK或总激肽原的血浆高5至6倍。用纯化的HMWK将总激肽原缺乏的血浆重构至正常水平(0.67 microM)可完全纠正其低于正常的抑制活性。然而,将HMWK缺乏的血浆重构至低分子量激肽原的正常水平(2.4 microM)并不能完全纠正该血浆低于正常的钙蛋白酶抑制能力。这些研究表明,HMWK既是血小板钙蛋白酶的有效抑制剂,也是其底物,并且血浆和细胞激肽原可能作为胞质钙激活半胱氨酸蛋白酶的调节剂发挥作用。